Saphris (SA-fris), a new atypical antipsychotic for schizophrenia and bipolar disorder

October 2009

Reps will promote Saphris (SA-fris), a new atypical antipsychotic for schizophrenia and bipolar disorder.

They will point out that Saphris (asenapine) seems well tolerated.

Saphris does seem to cause less weight gain and other metabolic problems than risperidone or Zyprexa (olanzapine).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Influenza using antivirals and vaccines for the current flu season
Interaction alerts often pop up about possible serotonin syndrome when patients get more than one serotonergic drug
Diabetes questions about how to switch between insulins
Women's Health You'll hear more about limiting antidepressants during pregnancy
Women's Health whether Yaz and Yasmin (drospirenone/ethinyl estradiol) are riskier than other combined oral contraceptives
Cardiology whether a DOUBLE dose of clopidogrel (Plavix) improves outcomes in cardiac patients
Generics Many big drugs will go generic in the next few years
Neurology & Pain Embeda (im-BED-a) is a new oral opioid designed to limit abuse
Psychiatry Saphris (SA-fris), a new atypical antipsychotic for schizophrenia and bipolar disorder
Respiratory & Allergy Xopenex (levalbuterol) does NOT work any better than albuterol
Respiratory & Allergy new OTC cough and cold syrup called Clofera (chlophedianol/pseudoephedrine)
Statins More questions about resolving statin myopathy will come up
Ophthalmology Claritin Eye and Zyrtec Itchy Eye Drops don't contain the active ingredient that you'd expect